Global sales of fondaparinux reported by GSK for the 2008 CY were US$315m, up +57.5% over 2007 CY sales of US$200m. Alchemia anticipates that its US marketing partner Dr Reddys Inc will take a SIGNIFICANT share of the market soon after launch...with no likely competition...Scheduled for end of 2009.
Looks good for that multibagger no 1 or no 2 dont care which comes first..
Ann: Half Yearly Report and Accounts , page-2
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable